

2023-2027 Georgia Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/2334125326A7EN.html

Date: September 2023

Pages: 0

Price: US\$ 2,500.00 (Single User License)

ID: 2334125326A7EN

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the



rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.



Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies



Contents

- I. INTRODUCTION
- **II. MARKET OVERVIEW**
- **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**
- IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
- V. ALTERNATIVE MARKET PENETRATION STRATEGIES
- VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

- 1. Introduction
- 2. Cancer Diagnostic Classification
- 3. ACTH
- 4. Alpha-Fetoprotein (AFP)
- 5. Beta-2 Microglobulin
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. Calcitonin
- 10. Carcinoembrionic Antigen (CEA)
- 11. Estrogen and Progesterone Receptors
- 12. Ferritin
- 13. Gastrin
- 14. Human Chorionic Gonadotropin (HCG)
- 15. Insulin
- 16. NSE
- 17. Occult Blood



- 18. PAP Smear/HPV
- 19. Prostatic Acid Phosphatase (PAP)
- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Cancer Diagnostics
- 27. Oncogenes
- : :Abl/abl-bcr
- : :AIB1
- : :BCL-2
- : :BRCA1
- : :CD44
- : :C-fos
- : :C-myb
- : :C-myc
- : :CYP-17
- : :Erb-B
- : :HPC1
- : :N-myc
- : :P40
- : :P51
- : :P53
- : :PIK3CA
- : :PTI-1
- : :Ras
- : :Reg
- : :Sis
- : :Src and others
- 28. Polypeptide Growth Factors
- : :Basic Fibroblast Growth Factor
- : :Beta-TGF
- : :Cachectin (TNT)
- : :Calmodulin
- : :ECFR
- : :Nerve Growth Factor (NGF)
- : :Epidermal Growth Factor (EGF)



 : :Ornithine Decarboxylase

 : :Transferrin

 : :Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

 : :Alpha-Interferon

 : :B Cell Growth Factors

 : :B Cell Growth Factor (BCGF)

 : :Gamma-Interferon

 : :Interleukin-1 (IL-1)

 : :Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Cancer Diagnostics

 : :N-Acetylglucosamine

 : :Actin

 : :Alpha-Actin

 : :Antineuronal Antibodies

 : :7B2

 : :B72.3

 : :Bax

 : :BCD-F9

 : :BLCA-4

 : :Blood Group Antigens A,B,H

 : :CA

 : :CA 72-4/TAG-72

 : :CA

 : :CA-242

 : :CA-549

 : :CAM

 : :CAR-3

 : :Cathepsin-D

 : :Chromogranin A and B

 : :Cluster 1 Antigen

 : :Cluster-5/5A Antigen

 : :CTA

 : :CU18

 : :DR-70

 : :DU-PAN-2



 : :Endometrial Bleeding Associated Factor

 : :Endostatin

 : :Epithelial Membrane Antigen

 : :Feulgen Hydrolysis

 : :Fibronectin

 : :FSH

 : :(1-\$\$\$\$3)-L-fucosyltransferase

 : :Gastrin-Releasing Peptide (GRP)

 : :GDCFP-15

 : :Glucagon

 : :Glycoamines

 : :H23

 : :Her-2

 : :Human Carcinoma Antigen

 : :HPA

 : :HSP27

 : :Intermediate Filaments

 : :Cytokeratins/CK18/Cyfra 21-1

 : :Desmin

 : :Gliofibrillary Acid Protein

 : :Neurofilaments

 : :Vimentin

 : :KA

 : :Kinases

 : :KP16D3

 : :LAI

 : :Leukocyte Common Antigen

 : :Lewis Antigens

 : :Lysophosphatidic Acid (LPA)

 : :Ma 695/Ma

 : :MABDF3

 : :MAG

 : :ME1

 : :Minactivin

 : :MN/CA9

 : :MSA

 : :Mucin Cancer Antigen (MCA)

 : :Multiple Tumor Suppressor

 : :Myosin



 : :NEA-130

 : :NMP22

 : :OA-519

 : :Opiod Peptides

 : :P-glycoprotein

 : :Pancreatic Oncofetal Antigen (POA)

 : :Placental Lactogen

 : :PR92

 : :Proliferative Index, Ki-67

 : :Px

 : :RB Inactivation/Deletion

 : :Ret

 : :SCCL

 : :Selectin

 : :Sialic Acid

 : :Sialyl SSEA-1/SLX

 : :SN10

 : :Somatostatin

 : :TA-90

 : :TABA

 : :Tachykinin

 : :TAG

 : :TPS

 : :Troponin

 : :Tubulin

 : :VCAM

 : :VEGF

 : :Villen and others

VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS

IX. CURRENT AND EMERGING TECHNOLOGIES

- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
- 3. Molecular Diagnostics
- 4. Chromosome Analysis
- a. Chronic Myelogenous Leukemia (CML)



- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies

X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

XI. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and

start-up companies with innovative technologies and products, including:

 : :Abbott

 : :Affymetrix

 : :Beckman Coulter/Danaher/Cepheid

 : :Becton Dickinson

 : :bioMerieux

 : :Bio-Rad

 : :DiaSorin

 : :Eiken Chemical

 : :Elitech Group

 : :Enzo Biochem

 : :Fuifilm Wako

 : :Fujirebio

 : :Grifols

 : :Hologic

 : :Leica Biosystems

 : :PerkinElmer

 : :Qiagen

 : :QuidelOrtho

 : :Roche



 : :Siemens Healthineers

 : :Takara Bio

 : :Thermo Fisher and others.



List Of Tables

LIST OF TABLES

Cancer Diagnostic Test Volume and Sales Forecasts

Cancer Diagnostic Volume Forecast by Test

Cancer Diagnostics Sales Forecast by Test

ACTH Test Volume and Diagnostics Sales Forecast

AFP Test Volume and Diagnostics Sales Forecast

Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast

CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast

CA 19-9 Test Volume and Diagnostics Sales Forecast

CA-125 Test Volume and Diagnostics Sales Forecast

Calcitonin Test Volume and Diagnostics Sales Forecast

Cathepsin Test Volume and Diagnostics Sales Forecast

CEA Test Volume and Diagnostics Sales Forecast

Chromogranin Test Volume and Diagnostics Sales Forecast

Colon-specific Antigen Test Volume and Diagnostics Sales Forecast

Cytokeratins Test Volume and Diagnostics Sales Forecast

Estrogen Receptor Test Volume and Diagnostics Sales Forecast

Ferritin Test Volume and Diagnostics Sales Forecast

Gastrin Test Volume and Diagnostics Sales Forecast

HCG Test Volume and Diagnostics Sales Forecast

Insulin Test Volume and Diagnostics Sales Forecast

Interferons Test Volume and Diagnostics Sales

Interleukins Test Volume and Diagnostics Sales Forecast

Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast

NSE Test Volume and Diagnostics Sales Forecast

Nucleolar Test Volume and Diagnostics Sales Forecast

Occult Blood Test Volume and Diagnostics Sales Forecast

Oncogenes Test Volume and Diagnostics Sales Forecast

Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast

PAP Smear Test Volume and Diagnostics Sales Forecast Parathyroid

Hormone Test Volume and Diagnostics Sales Forecast Progesterone

Receptor Test Volume and Diagnostics Sales Forecast PAP Test

Volume and Diagnostics Sales Forecast

PSA Test Volume and Diagnostics Sales Forecast

S-100 Protein Test Volume and Diagnostics Sales Forecast

Serotonin Test Volume and Diagnostics Sales Forecast



Sialic Acid Test Volume and Diagnostics Sales Forecast

Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast

TDT Test Volume and Diagnostics Sales Forecast

Thymidine Kinase Test Volume and Diagnostics Sales Forecast

Thyroglobulin Test Volume and Diagnostics Sales Forecast

TPA Test Volume and Diagnostics Sales Forecast

Cancer Diagnostic Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Sub-classification Tests

Biochemical Markers Potential Applications in Cancer Diagnosis

Oncogenes Potential Applications in Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications in Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications in Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis



I would like to order

Product name: 2023-2027 Georgia Tumor Markers Testing Market-High-Growth Opportunities for Cancer

Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation

Pipeline, Emerging Opportunities for Suppliers

Product link: https://marketpublishers.com/r/2334125326A7EN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2334125326A7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

**All fields are required
Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$